Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.
Press releases published on May 30, 2025
CORRECTION: VivoPower Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private Placement Priced at US$6.05 Per Share, Above Last Market Closing Price Under NASDAQ Rules
GlobeNewswire
·
May 30, 2025
LONDON, May 30, 2025 (GLOBE NEWSWIRE) -- VivoPower International PLC (Nasdaq: VVPR) hereby issues a correction regarding its press release dated 28 May 2025, titled "VivoPower Announces XRP-Focused Digital Asset Treasury Strategy and US$121 Million Private …
XDC Network Partners with Bitso Business to Power Cross-Border Payments from the U.S. to Mexico
GlobeNewswire
·
May 30, 2025
Mexico City, Mexico, May 30, 2025 (GLOBE NEWSWIRE) -- The XDC Network, a leading blockchain platform for real-world finance, is proud to announce a strategic partnership with Bitso Business - the B2B arm of Bitso that provides infrastructure for efficient …
Blue and Red BV Joins Forces with ScreenCom BV to Create Integrated Workspace Technology Leader
GlobeNewswire
·
May 30, 2025
AMSTERDAM, May 30, 2025 (GLOBE NEWSWIRE) -- Blue and Red BV, a specialist in digital signage and workspace management technology, today announced the successful completion of its strategic merger with ScreenCom BV, a leading provider of enterprise digital …
Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers
GlobeNewswire
·
May 30, 2025
SEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, …
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
GlobeNewswire
·
May 30, 2025
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of …
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
GlobeNewswire
·
May 30, 2025
RESEARCH TRIANGLE PARK, N.C., May 30, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data which highlights the reduction in the percentage of days with hereditary angioedema (HAE) symptoms among young children …
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
GlobeNewswire
·
May 30, 2025
PRINCETON, N.J., May 30, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in …
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
GlobeNewswire
·
May 30, 2025
DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil"), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced that Bronson Crouch, Chief Executive Officer, will present at …
Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
GlobeNewswire
·
May 30, 2025
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant …
Arvinas to Present at Jefferies Global Healthcare Conference
GlobeNewswire
·
May 30, 2025
NEW HAVEN, Conn., May 30, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that management will participate in a …
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
GlobeNewswire
·
May 30, 2025
Zanidatamab is the first and only dual HER2-targeted bispecific antibody approved for HER2+ biliary tract cancer in China; conditional approval based on the results of the HERIZON-BTC-01 clinical study $20 million milestone payment to be received from …
XDC Network Partners with Bitso Business to Power Cross-Border Payments from the U.S. to Mexico
GlobeNewswire
·
May 30, 2025
Mexico City, Mexico, May 30, 2025 (GLOBE NEWSWIRE) -- The XDC Network, a leading blockchain platform for real-world finance, is proud to announce a strategic partnership with Bitso Business - the B2B arm of Bitso that provides infrastructure for efficient …
Best VPN for Streaming (2025): IPVanish Recognized as Top Streaming VPN by Software Experts
GlobeNewswire
·
May 30, 2025
NEW YORK CITY, May 30, 2025 (GLOBE NEWSWIRE) -- Software Experts has recognized IPVanish as the Best VPN for Streaming in 2025, citing its strong performance across speed, server coverage, privacy features, and usability. The review highlights IPVanish’s …
Aurora Mobile's GPTBots.ai Welcomes the Enhanced DeepSeek-R1-0528 Model to Power Enterprise AI Solutions
GlobeNewswire
·
May 30, 2025
SHENZHEN, China, May 30, 2025 (GLOBE NEWSWIRE) -- Aurora Mobile Limited (NASDAQ: JG) ("Aurora Mobile" or the "Company"), a leading provider of customer engagement and marketing technology services in China, today announced the integration of newly updated …
ScreenCom BV Expands Digital Signage Ecosystem Through Strategic Merger with Blue and Red BV
GlobeNewswire
·
May 30, 2025
AMSTERDAM, May 30, 2025 (GLOBE NEWSWIRE) -- ScreenCom BV, a leading provider of enterprise digital signage solutions, today announced the successful completion of its merger with Blue and Red BV, a specialist in digital signage and workspace management …
Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025
GlobeNewswire
·
May 30, 2025
Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 months Survival has currently reached plateau, with 34% (7/20) of patients still alive 80% of patients treated with …
Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies
GlobeNewswire
·
May 30, 2025
Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided …
Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO
GlobeNewswire
·
May 30, 2025
L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO L’étude AERIFY-1 a atteint son objectif principal, à savoir une réduction statistiquement significative des exacerbations modérées ou sévères chez …
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
GlobeNewswire
·
May 30, 2025
AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically meaningful benefit AERIFY-2, a second Phase 3 trial, did …
Quantum eMotion Announces Brokered LIFE Financing of C$6,000,000
GlobeNewswire
·
May 30, 2025
NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES MONTREAL, May 29, 2025 (GLOBE NEWSWIRE) -- Quantum eMotion Corp. (“QeM” or the “Corporation”) (TSX.V: QNC; OTCQB: QNCCF) is pleased to announce a best efforts brokered …